A Cutaneous Presentation Secondary to COVID-19
DOI:
https://doi.org/10.60591/crspmi.134Keywords:
Adrenal Cortex Hormones, Colchicine, COVID-19/complications, Vasculitis, Leukocytoclastic, Cutaneous/diagnosis, Vasculitis, Leukocytoclastic, Cutaneous/drug therapyAbstract
.
Downloads
References
Frumholtz L, Laurent-Roussel S, Lipsker D, Terrier B. Cutaneous vasculitis: review on diagnosis and clinicopathologic correlations. clin Rev Allergy Immunol. 2021;61:181-193. doi: 10.1007/s12016-020-08788-4.
Koutkia P, Mylonakis E, Rounds S, Erickson A. Leucocytoclastic vasculitis: an update for the clinician. Scand J Rheumatol. 2001;30:315-22. doi: 10.1080/030097401317148499. .
Wong K, Farooq Alam Shah MU, Khurshid M, Ullah I, Tahir MJ, Yousaf Z. COVID-19 associated vasculitis: A systematic review of case reports and case series. Ann Med Surg. 2022;74:103249. doi: 10.1016/j.amsu.2022.103249.
Capoferri G, Daikeler T, Mühleisen B, Trendelenburg M, Müller S. Cutaneous leukocytoclastic vasculitis secondary to COVID-19 infection leading to extensive skin necrosis. Clin Dermatol. 2022;40:397-401. doi: 10.1016/j.clindermatol.2022.02.013.
Fraticelli P, Benfaremo D, Gabrielli A. Diagnosis and management of leukocytoclastic vasculitis. Intern Emerg Med. 2021;16:831-41. doi: 10.1007/s11739-021-02688-x.